Inhibitors

Edit

Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Nasdaq Globe Newswire 24 Feb 2026

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 ... .

Edit

Material Agreement (Form 8-K) (Inhibitor Therapeutics Inc)

Public Technologies 24 Feb 2026

) Item 1.01. Entry into a Material Definitive Agreement. Securities Purchase Agreement. On February 19, 2026, Inhibitor Therapeutics, Inc ... The SPA also includes customary representations, warranties and covenants ... Disclaimer. Inhibitor Therapeutics Inc.

Edit

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor (Form 6-K) (AC Immune Ltd)

Public Technologies 24 Feb 2026

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor · ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor. · NLRP3 inhibitors are a major new class of ...

Edit

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer (IP Group plc)

Public Technologies 24 Feb 2026

... breast cancer who are eligible to receive a PARP inhibitor ... "Importantly, breast cancer patients with a BRCA mutation often develop resistance to treatment with a PARP inhibitor alone.

Edit

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Pharmiweb 24 Feb 2026

Whether evaluating the pooled data or 100mg Phase 3 formulation data, PFS was two or nearly three times longer relative to published data from studies with the only marketed HIF-2a inhibitor in the same patient population.”.

Edit

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for ...

Nasdaq Globe Newswire 23 Feb 2026

Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer ... .

Edit

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One ...

The Galveston Daily News 23 Feb 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Feb 23, 2026-- ....

Edit

Discovery Could Make Immune Checkpoint Inhibitors Safer

Milton Independent 21 Feb 2026

Experts at Cincinnati Children's report proof-of-concept results that may sharply reduce the risk of a lethal side effect that has negatively impacted the use of revolutionary cancer immunotherapies ....

Edit

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis (Castle Biosciences Inc)

Public Technologies 20 Feb 2026

Results from the independent validation cohort demonstrated that approximately 30 percent of patients studied were identified by the AdvanceAD-Tx test as having a JAK Inhibitor Responder Profile.

Edit

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society ...

Nasdaq Globe Newswire 19 Feb 2026

COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study ...

Edit

Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma

The Galveston Daily News 19 Feb 2026

DOVER, Del. & EPALINGES, Switzerland--(BUSINESS WIRE)--Feb 19, 2026-- ....

Edit

Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Market Research Report 2026: Soliris and Ultomiris ...

Nasdaq Globe Newswire 19 Feb 2026

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration ...

Edit

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

PR Newswire 19 Feb 2026

Approval of JAK Inhibitors ... Emergence of OX40L and IL-2 Inhibitors. Emerging therapies, including OX40L and IL-2 inhibitors, are strengthening the alopecia areata landscape by targeting the disease's root causes and offering precision in treatment.

Edit

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 (Form 8-K) (Cocrystal Pharma Inc)

Public Technologies 19 Feb 2026

CDI-988 was designed and developed using the Company's proprietary structure-based drug discovery platform technology as a pan-viral protease inhibitor, targeting 3CL viral proteases.

Edit

Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development

Times Argus 18 Feb 2026

... its voltage-gated sodium channel (NaV) 1.8 inhibitor.

Podcasts:

Latest News for: inhibitors

Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Material Agreement (Form 8-K) (Inhibitor Therapeutics Inc)

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor (Form 6-K) (AC Immune Ltd)

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer (IP Group plc)

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for ...

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One ...

Discovery Could Make Immune Checkpoint Inhibitors Safer

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis (Castle Biosciences Inc)

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society ...

Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma

Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Market Research Report 2026: Soliris and Ultomiris ...

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 (Form 8-K) (Cocrystal Pharma Inc)

Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development

Article Search

EXPLORE WN.com